134 related articles for article (PubMed ID: 17296591)
1. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.
Auwerda JJ; Sonneveld P; de Maat MP; Leebeek FW
Haematologica; 2007 Feb; 92(2):279-80. PubMed ID: 17296591
[TBL] [Abstract][Full Text] [Related]
2. Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment.
Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM
J Thromb Haemost; 2003 Mar; 1(3):445-9. PubMed ID: 12871448
[TBL] [Abstract][Full Text] [Related]
3. Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders.
Auwerda JJ; Sonneveld P; de Maat MP; Leebeek FW
Clin Lymphoma Myeloma; 2007 Jul; 7(7):462-6. PubMed ID: 17875234
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
van Marion AM; Auwerda JJ; Lisman T; Sonneveld P; de Maat MP; Lokhorst HM; Leebeek FW
Leuk Res; 2008 Jul; 32(7):1078-84. PubMed ID: 18241919
[TBL] [Abstract][Full Text] [Related]
5. Aquaporin 2 gene variations, risk of venous thrombosis and plasma levels of von Willebrand factor and factor VIII.
Nossent AY; Vos HL; Rosendaal FR; Bertina RM; Eikenboom JC
Haematologica; 2008 Jun; 93(6):959-60. PubMed ID: 18515885
[No Abstract] [Full Text] [Related]
6. Temporary relief of symptomatic Von Willebrand disease by multiple myeloma.
Auwerda JJ; Sonneveld P; Leebeek FW
J Thromb Haemost; 2005 May; 3(5):1088-9. PubMed ID: 15869614
[No Abstract] [Full Text] [Related]
7. [Venous thromboembolic disease: which coagulation screening, for whom, when?].
Wautrecht JC
Rev Med Brux; 2005 Sep; 26(4):S315-9. PubMed ID: 16240880
[TBL] [Abstract][Full Text] [Related]
8. Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.
Tiong IS; Rodgers SE; Lee CH; McRae SJ
Leuk Lymphoma; 2017 Apr; 58(4):941-949. PubMed ID: 27931131
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system.
Ågren A; Holmström M; Schmidt DE; Hosokawa K; Blombäck M; Hjemdahl P
Thromb Haemost; 2017 Jan; 117(1):75-85. PubMed ID: 27761577
[TBL] [Abstract][Full Text] [Related]
10. Effect of intravenous high-dose methylprednisolone on coagulation and fibrinolysis markers.
Frank RD; Altenwerth B; Brandenburg VM; Nolden-Koch M; Block F
Thromb Haemost; 2005 Aug; 94(2):467-8. PubMed ID: 16116692
[No Abstract] [Full Text] [Related]
11. Acquired von Willebrand disease and multiple myeloma: a case report of a breast cancer survivor.
Jin N; Salahuddin FF; Nesbitt JA
Blood Coagul Fibrinolysis; 2014 Dec; 25(8):890-3. PubMed ID: 24911454
[TBL] [Abstract][Full Text] [Related]
12. Long-term increased factor VIII levels are associated to interleukin-6 levels but not to post-thrombotic syndrome in patients with deep venous thrombosis.
Bittar LF; Mazetto Bde M; Orsi FL; Collela MP; De Paula EV; Annichino-Bizzacchi JM
Thromb Res; 2015 Mar; 135(3):497-501. PubMed ID: 25575413
[TBL] [Abstract][Full Text] [Related]
13. Prothrombotic State Induced by Middle-Distance Endurance Exercise in Middle-Aged Athletes.
Lippi G; Salvagno GL; Tarperi C; Gelati M; Montagnana M; Danese E; Festa L; Sanchis-Gomar F; Favaloro EJ; Schena F
Semin Thromb Hemost; 2018 Nov; 44(8):747-755. PubMed ID: 30119138
[TBL] [Abstract][Full Text] [Related]
14. Search for coagulopathy does not obviate search for venous thrombosis in suspected paradoxical embolism.
Stöllberger C; Finsterer J
Stroke; 2003 Sep; 34(9):e146-7; author reply e146-7. PubMed ID: 12920257
[No Abstract] [Full Text] [Related]
15. Absence of a bleeding tendency in severe acquired von Willebrand's disease. The role of platelet von Willebrand factor in maintaining normal hemostasis.
Drouin J; Lillicrap DP; Izaguirre CA; Sutherland M; Windsor S; Benford K; Hoogendorn H; Giles AR
Am J Clin Pathol; 1989 Oct; 92(4):471-8. PubMed ID: 2508465
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor.
Shinagawa A; Kojima H; Berndt MC; Kaneko S; Suzukawa K; Hasegawa Y; Shigeta O; Nagasawa T
Thromb Haemost; 2005 May; 93(5):889-96. PubMed ID: 15886805
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor: another janus-faced hemostasis protein.
Franchini M; Mannucci PM
Semin Thromb Hemost; 2008 Oct; 34(7):663-9. PubMed ID: 19085767
[TBL] [Abstract][Full Text] [Related]
18. Antiphospholipid antibodies, haemostatic variables and thrombosis--a survey of 144 patients.
Ames PR; Pyke S; Iannaccone L; Brancaccio V
Thromb Haemost; 1995 May; 73(5):768-73. PubMed ID: 7482401
[TBL] [Abstract][Full Text] [Related]
19. Plasma Levels of Vascular Endothelial Growth Factor and Selected Hemostatic Parameters in Association With Treatment Response in Multiple Myeloma.
Sokol J; Hrncar M; Nehaj F; Stasko J
Clin Appl Thromb Hemost; 2019; 25():1076029618823280. PubMed ID: 30845824
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease.
Cushing M; Kawaguchi K; Friedman KD; Mark T
Transfusion; 2012 Jul; 52(7):1535-41. PubMed ID: 22229973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
